Analyzing the Biological Entity of Nanomaterials - Safety of Nanomaterials along Their Lifecycle - page 92

Rugonyi, S., Biswas, S. C., and Hall, S. B. (2008). The biophysical function of pulmonary
surfactant. Respir Physiol Neurobiol 163:244-255.
Sachan, A. K., Harishchandra, R. K., Bantz, C. et al. (2012). High-resolution investigation
of nanoparticle interaction with a model pulmonary surfactant monolayer. ACS Nano
6:1677-1687.
Salvador-Morales, C., Townsend, P., Flahaut, E. et al. (2007). Binding of pulmonary surfactant
proteins to carbon nanotubes; potential for damage to lung immune defense mecha-
nisms. Carbon 45:607-617.
Sanders, N., Rudolph, C., Braeckmans, K. et al. (2009). Extracellular barriers in respiratory
gene therapy. Adv Drug Del Rev 61:115-127.
Sayes, C. M., Reed, K. L., Subramoney, S. et al. (2008). Can in vitro assays substitute for
in vivo studies in assessing the pulmonary hazards of fine and nanoscale materials?
J Nanopart Res 11:421-431.
Sayes, C. M., and Warheit, D. B. (2009). Characterization of nanomaterials for toxicity assess-
ment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:660-670.
Schleh, C., Mühlfeld, C., Pulskamp, K. et al. (2009). The effect of titanium dioxide nanopar-
ticles on pulmonary surfactant function and ultrastructure. Respir Res 10 (90):1-11.
Schleh, C., Rothen-Rutishauser, B., and Kreyling, W. G. (2011). The influence of pulmo-
nary surfactant on nanoparticulate drug delivery systems. Eur J Pharm Biopharm
77:350-352.
Schulze, C., Schaefer, U. F., Ruge, C. A. et al. (2011). Interaction of metal oxide nanoparticles
with lung surfactant protein A. Eur J Pharm Biopharm 77:376-383.
Schulze, C., Schulze, C., Kroll, A. et al. (2008). Not ready to use—Overcoming pitfalls when
dispersing nanoparticles in physiological media. Nanotoxicology 2:51-61.
Schürch, S., Gehr, P., Im Hof, V. et al. (1990). Surfactant displaces particles toward the epithe-
lium in airways and alveoli. Respir Physiol 80:17-32.
Serrano, A. G., and Pérez-Gil, J. (2006). Protein-lipid interactions and surface activity in the
pulmonary surfactant system. Chem Phys Lipids 141:105-118.
Shang, L., Wang, Y., Jiang, J. et al. (2007). pH-dependent protein conformational changes
in albumin:gold nanoparticle bioconjugates: a spectroscopic study. Langmuir
23:2714-2721.
Shemetov, A. A., Nabiev, I., and Sukhanova, A. (2012). Molecular interaction of proteins and
peptides with nanoparticles. ACS Nano 6:4585-4602.
Tatur, S., and Badia, A. (2012). Influence of hydrophobic alkylated gold nanoparticles on
the phase behavior of monolayers of dppc and clinical lung surfactant. Langmuir
28:628-639.
Tenzer, S., Docter, D., Kuharev, J. et al. (2013). Rapid formation of plasma protein corona
critically affects nanoparticle pathophysiology. Nat Nanotechnol 8:772-781.
Tenzer, S., Docter, D., Rosfa, S. et al. (2011). Nanoparticle size is a critical physicochemi-
cal determinant of the human blood plasma corona: A comprehensive quantitative pro-
teomic analysis. ACS Nano 5:7155-7167.
van der Zande, M., Vandebriel, R. J., Van Doren, E. et al. (2012). Distribution, elimination, and
toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. ACS
Nano 6:7427-7442.
Vroman, L., Adams, A. L., Fischer, G. C. et al. (1980). Interaction of high molecular weight
kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood 55:156-159.
Walczyk, D., Bombelli, F. B., Monopoli, M. P. et al. (2010). What the cell “sees” in bionano-
science. J Am Chem Soc 132:5761-5768.
Walkey, C. D., and Chan, W. C. W. (2012). Understanding and controlling the interac-
tion of nanomaterials with proteins in a physiological environment. Chem Soc Rev
41:2780-2799.